Paradigm Biopharmaceuticals Limited (ASX:PAR)
0.1700
0.00 (0.00%)
Jul 10, 2026, 4:10 PM AEST
ASX:PAR Stock Forecast
ASX-PAR's stock price has decreased by -60.92% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, ASX:PAR stock has a consensus rating of "Strong Buy" and an average price target of $1.37. The average 1-year stock price forecast is 705.88% higher than the current stock price, while the lowest is $0.45 (+164.71%) and the highest is $2.29 (+1,247.06%).
Price Target: $1.37 (+705.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ASX:PAR stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bell Potter | Bell Potter | Buy Maintains $0.45 | Buy | Maintains | $0.45 | +164.71% | Jun 18, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.09
from -0.06
EPS Next Year
-0.09
from -0.09
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.09 | ||
| Avg | -0.09 | ||
| Low | -0.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |